Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Teva (TEVA) Stock Price & Analysis

62 Followers

TEVA Stock Chart & Stats

ILA 13,300.00ILA 120.00(0.91%)
At close:
ILA 11KILA 12KILA 13KAug 10Aug 24Sep 7Sep 22Oct 5Oct 19Nov 2
Day’s Range
ILA 13,160.00 - ILA 13,390.00
52-Week Range
ILA 7,732.00 - ILA 13,570.00
Previous Close
ILA 13,180.00
Volume
N/A
Average Volume (3M)
1.79M
Market Cap
ILS 153.59B
Enterprise Value
ILS 185.30B
Total Cash (Recent Filing)
ILS 4.13B
Total Debt (Recent Filing)
ILS 17.16B
Price to Earnings (P/E)
92.8
Beta
0.59
Next Earnings
Feb 10, 2027 (Est.)
EPS Estimate
211.31
Last Dividend Ex-Date
Nov 28, 2017
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Innovative Portfolio Growth

Strong growth across Teva’s innovative brands is improving the company’s mix beyond traditional generics. Raised guidance for AUSTEDO, AJOVY and UZEDY supports continued revenue expansion, broader product diversification and greater earnings durability over the next several quarters.

Cash Generation And Deleveraging

Substantial operating and free cash flow gives Teva internal funding capacity while supporting debt service and balance-sheet repair. The long-term debt reduction record and positive cash generation should improve financial flexibility, reduce financing pressure and support investment in growth.

Biosimilar Platform Expansion

A sizable marketed and pipeline biosimilar portfolio creates a scalable growth platform alongside Teva’s generic and specialty businesses. Leading positions in several U.S. products may strengthen commercial reach, while portfolio breadth can support recurring launches and diversification.

Bears Say

Elevated Leverage

Despite meaningful debt repayment, Teva still carries substantial absolute debt and elevated debt relative to equity. This limits balance-sheet flexibility and leaves cash flow more exposed to interest expense, refinancing needs or weaker operating performance if profitability softens.

Thin And Volatile Profitability

The return to profitability is encouraging, but the low current net margin and recent history of large losses indicate that earnings power is not yet fully stabilized. Thin margins leave less buffer against pricing pressure, product mix changes or unexpected operating setbacks.

Generic Revenue Pressure

Generics remain Teva’s core business, yet reported revenue is being pressured by the lower REVLIMID contribution and the outlook calls for only flat-to-slight growth. This constrains near-term top-line expansion and increases reliance on specialty products and biosimilars.

Teva News

TEVA FAQ

What was Teva’s price range in the past 12 months?
Teva lowest stock price was ILA 7732.00 and its highest was ILA 13570.00 in the past 12 months.
What is Teva’s market cap?
Teva’s market cap is ₪153.59B.
When is Teva’s upcoming earnings report date?
Teva’s next earnings report is estimated for Feb 10, 2027 (not yet confirmed), which is in 95 days.
How were Teva’s earnings last quarter?
Teva released its earnings results on Nov 03, 2026. The company reported ILA 271.235 earnings per share for the quarter, beating the consensus estimate of ILA 227.396 by ILA 43.839.
Is Teva overvalued?
According to Wall Street analysts Teva’s price is currently Undervalued.
Does Teva pay dividends?
Teva pays a Quarterly dividend of ILA 8.5 which represents an annual dividend yield of ―. See more information on Teva dividends here
What is Teva’s EPS estimate?
Teva’s EPS estimate is 211.31.
How many shares outstanding does Teva have?
Teva has 1,166,826,800 shares outstanding.
What happened to Teva’s price movement after its last earnings report?
Teva reported an EPS of ILA 271.235 in its last earnings report, beating expectations of ILA 227.396. Following the earnings report the stock price went up 3.746%.
Which hedge fund is a major shareholder of Teva?
Currently, no hedge funds are holding shares in IL:TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology